CY1116304T1 - Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας - Google Patents

Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας

Info

Publication number
CY1116304T1
CY1116304T1 CY20151100243T CY151100243T CY1116304T1 CY 1116304 T1 CY1116304 T1 CY 1116304T1 CY 20151100243 T CY20151100243 T CY 20151100243T CY 151100243 T CY151100243 T CY 151100243T CY 1116304 T1 CY1116304 T1 CY 1116304T1
Authority
CY
Cyprus
Prior art keywords
biotine
therapeutic treatment
treatment
biotin
relates
Prior art date
Application number
CY20151100243T
Other languages
English (en)
Inventor
Frédéric Sedel
Original Assignee
Assistance Publique Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hôpitaux De Paris filed Critical Assistance Publique Hôpitaux De Paris
Publication of CY1116304T1 publication Critical patent/CY1116304T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση της βιοτίνης για τη θεραπευτική αγωγή της σκλήρυνσης κατά πλάκας, ειδικότερα δε των προοδευτικών μορφών και των νευρολογικών επακολουθών αυτής.
CY20151100243T 2012-07-26 2015-03-11 Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας CY1116304T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1257254A FR2993780B1 (fr) 2012-07-26 2012-07-26 Methode de traitement de la sclerose en plaque
US13/644,615 US8835487B2 (en) 2012-07-26 2012-10-04 Method of treating multiple sclerosis
EP13719836.2A EP2729143B1 (en) 2012-07-26 2013-04-29 Use of biotin for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
CY1116304T1 true CY1116304T1 (el) 2017-02-08

Family

ID=47294963

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100243T CY1116304T1 (el) 2012-07-26 2015-03-11 Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας

Country Status (25)

Country Link
US (5) US8835487B2 (el)
EP (2) EP2729143B1 (el)
JP (1) JP6208235B2 (el)
KR (1) KR101967502B1 (el)
CN (2) CN104602689A (el)
AU (1) AU2013295370B2 (el)
BR (1) BR112015001562A2 (el)
CA (1) CA2879434C (el)
CY (1) CY1116304T1 (el)
DK (2) DK2857019T3 (el)
EA (1) EA030478B1 (el)
ES (3) ES2811074T3 (el)
FR (1) FR2993780B1 (el)
HK (1) HK1207583A1 (el)
HR (1) HRP20150260T1 (el)
HU (1) HUE024558T2 (el)
IL (1) IL236790A (el)
LT (1) LT2857019T (el)
ME (1) ME02060B (el)
PL (1) PL2729143T3 (el)
PT (2) PT2857019T (el)
RS (1) RS53893B1 (el)
SI (2) SI2729143T1 (el)
SM (1) SMT201500057B (el)
WO (1) WO2014016003A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
CN107531846B (zh) * 2015-02-13 2019-04-30 优迈特株式会社 含氟共聚物和以其作为有效成分的表面改性剂
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
RU2638803C2 (ru) * 2016-06-09 2017-12-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки биотина с замедленным высвобождением и способ их получения
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
US11938117B2 (en) 2016-09-01 2024-03-26 Nutrition21, LLC Magnesium biotinate compositions and methods of use
RU2639488C1 (ru) * 2017-04-06 2017-12-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция, содержащая биотин, и способ ее получения
WO2020102203A1 (en) * 2018-11-13 2020-05-22 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN112076310A (zh) * 2019-06-14 2020-12-15 苏州融析生物科技有限公司 一种治疗多发性硬化的药物组合物及其制备
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
JP2023509283A (ja) 2020-01-01 2023-03-08 セラジェネックス リサーチ （インディア） ピーブイティー リミテッド Ａｔｐ効率を向上するための相乗的栄養組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3609165A (en) 1968-07-19 1971-09-28 Research Corp 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes
JPH0995448A (ja) 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6664039B1 (en) 1998-10-14 2003-12-16 California Institute Of Technology Methods and compositions for modulating neurodegeneration
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
AU2003266287A1 (en) 2002-08-23 2004-03-11 Dsm Ip Assets B.V. Novel nutraceutical compositions comprising biotin
US7709028B2 (en) 2002-09-30 2010-05-04 Daiichi Pharmaceutical Co., Ltd. Particulate product comprising pantethine
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
BG66011B1 (bg) * 2005-05-25 2010-10-29 Райна Щонова Състав от растителен произход
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Also Published As

Publication number Publication date
DK2729143T3 (en) 2015-03-23
CN109908140A (zh) 2019-06-21
PL2729143T3 (pl) 2015-05-29
US10201528B2 (en) 2019-02-12
EP2729143A1 (en) 2014-05-14
US9351961B2 (en) 2016-05-31
SI2729143T1 (sl) 2015-05-29
EP2857019B1 (en) 2020-05-27
JP2015522630A (ja) 2015-08-06
HUE024558T2 (hu) 2016-02-29
FR2993780B1 (fr) 2015-02-13
CA2879434C (en) 2019-04-23
EA201590270A1 (ru) 2015-11-30
KR20150042799A (ko) 2015-04-21
RS53893B1 (en) 2015-08-31
WO2014016003A1 (en) 2014-01-30
FR2993780A1 (fr) 2014-01-31
CA2879434A1 (en) 2014-01-30
EP2857019A1 (en) 2015-04-08
LT2857019T (lt) 2020-09-10
ES2626079T3 (es) 2017-07-21
PT2729143E (pt) 2015-03-16
HK1207583A1 (en) 2016-02-05
HRP20150260T1 (hr) 2015-05-08
EA030478B1 (ru) 2018-08-31
ES2532364T3 (es) 2015-03-26
US20140348920A1 (en) 2014-11-27
BR112015001562A2 (pt) 2017-07-04
SI2857019T1 (sl) 2020-10-30
AU2013295370A1 (en) 2015-02-19
DK2857019T3 (da) 2020-08-17
US20190117625A1 (en) 2019-04-25
US20140030331A1 (en) 2014-01-30
US20160324830A1 (en) 2016-11-10
JP6208235B2 (ja) 2017-10-04
ME02060B (me) 2015-05-20
PT2857019T (pt) 2020-07-24
AU2013295370B2 (en) 2017-03-02
ES2811074T3 (es) 2021-03-10
SMT201500057B (it) 2015-05-05
KR101967502B1 (ko) 2019-04-09
EP2729143B1 (en) 2014-12-31
CN104602689A (zh) 2015-05-06
IL236790A (en) 2017-09-28
US8835487B2 (en) 2014-09-16
US20190117626A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
CY1116304T1 (el) Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
SMT201700034B (it) Composti di urea biciclica, tiourea, guanidina e cianoguanidina utili per il trattamento del dolore
BR112014026285A8 (pt) oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
TR201901886T4 (tr) DNA-PK inhibitörleri.
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
TR201903009T4 (tr) Musküler distrofi tedavisine yönelik ekson atlama bileşimleri.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
IN2015DN01524A (el)
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma